
Alex Harding to chase industry dreams at CRISPR Therapeutics; Scoop: Biogen’s head of business development splits for Kite
While Alex Harding is a practicing physician, he’s long envisioned a career on the business side of drug development. Next year, he’s seizing an opportunity to further those goals at CRISPR Therapeutics.
The Swiss-American company announced on Monday that Harding — one of Endpoints News’ 20 under 40 honorees in 2020 — is joining on Jan. 5 as SVP and head of business development. CEO Samarth Kulkarni said in a news release that the appointment will be “critical in driving the next phase of growth for CRISPR.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.